On Friday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) opened lower -3.59% from the last session, before settling in for the closing price of $1.67. Price fluctuations for BDTX have ranged from $1.54 to $7.66 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 47.59% at the time writing. With a float of $43.14 million, this company’s outstanding shares have now reached $56.64 million.
Let’s determine the extent of company efficiency that accounts for 24 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Black Diamond Therapeutics Inc (BDTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Black Diamond Therapeutics Inc is 23.86%, while institutional ownership is 64.85%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 47.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.75% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Check out the current performance indicators for Black Diamond Therapeutics Inc (BDTX). In the past quarter, the stock posted a quick ratio of 4.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit 0.10 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Looking closely at Black Diamond Therapeutics Inc (NASDAQ: BDTX), its last 5-days average volume was 3.3 million, which is a drop from its year-to-date volume of 3.41 million. As of the previous 9 days, the stock’s Stochastic %D was 5.68%. Additionally, its Average True Range was 0.21.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 3.43%, which indicates a significant decrease from 5.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.40% in the past 14 days, which was higher than the 77.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1006, while its 200-day Moving Average is $3.6228. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $1.6567. Second resistance stands at $1.7033. The third major resistance level sits at $1.7567. If the price goes on to break the first support level at $1.5567, it is likely to go to the next support level at $1.5033. Now, if the price goes above the second support level, the third support stands at $1.4567.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
There are currently 56,662K shares outstanding in the company with a market cap of 91.23 million. Presently, the company’s annual sales total 0 K according to its annual income of -69,680 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -15,990 K.
